170 related articles for article (PubMed ID: 27598026)
41. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
42. Associations of an abnormal Pap test result with attitudes and beliefs relevant to cervical cancer: a study of rural Appalachian women.
Crosby RA; Vanderpool R; Jones C
Cancer Causes Control; 2016 Jul; 27(7):947-50. PubMed ID: 27294724
[TBL] [Abstract][Full Text] [Related]
43. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
Ezat SW; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
[TBL] [Abstract][Full Text] [Related]
44. Limited Understanding of Pap Smear Testing among Women, a Barrier to Cervical Cancer Screening in the United Arab Emirates.
AL-Hammadi FA; Al-Tahri F; Al-Ali A; Nair SC; Abdulrahman M
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3379-3387. PubMed ID: 29286607
[TBL] [Abstract][Full Text] [Related]
45. Papanicolaou Test Rates Among Sexual Minority Women: A Systematic Review and Meta-Analysis.
McDonald KM; Delgado A; Roeckner JT
LGBT Health; 2022 Jan; 9(1):1-7. PubMed ID: 34665668
[No Abstract] [Full Text] [Related]
46. Cervical cancer screening among Lebanese women.
Bou-Orm IR; Sakr RE; Adib SM
Rev Epidemiol Sante Publique; 2018 Feb; 66(1):1-6. PubMed ID: 29249573
[TBL] [Abstract][Full Text] [Related]
47. Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.
Polyzos NP; Valachis A; Mauri D; Ioannidis JP
CMAJ; 2011 Apr; 183(6):E337-43. PubMed ID: 21402681
[TBL] [Abstract][Full Text] [Related]
48. Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis.
Vali M; Maleki Z; Nikbakht HA; Hassanipour S; Kouhi A; Nazemi S; Hajizade-Valokolaee M; Nayeb M; Ghaem H
BMC Womens Health; 2023 Dec; 23(1):671. PubMed ID: 38098009
[TBL] [Abstract][Full Text] [Related]
49. Effects of training based on the health belief model on Iranian women's performance about cervical screening: A systematic review and meta-analysis.
Simbar M; Ghazanfarpour M; Abdolahian S
J Educ Health Promot; 2020; 9():179. PubMed ID: 32953907
[TBL] [Abstract][Full Text] [Related]
50. Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening.
Viscondi JYK; Faustino CG; Campolina AG; Itria A; Soárez PC
Clinics (Sao Paulo); 2018 Jul; 73():e385. PubMed ID: 29995100
[TBL] [Abstract][Full Text] [Related]
51. Use of micronucleus assays for the prediction and detection of cervical cancer: a meta-analysis.
Setayesh T; Kundi M; Nersesyan A; Stopper H; Fenech M; Krupitza G; Knasmüller S
Carcinogenesis; 2020 Oct; 41(10):1318-1328. PubMed ID: 32780106
[TBL] [Abstract][Full Text] [Related]
52. The Short-Term Impact Of COVID-19 Pandemic on Cervical Cancer Screening: A Systematic Review and Meta-Analysis.
Sasidharanpillai S; Ravishankar N
Asian Pac J Cancer Prev; 2022 May; 23(5):1497-1504. PubMed ID: 35633530
[TBL] [Abstract][Full Text] [Related]
53. The Impact of the COVID-19 Pandemic on Breast and Cervical Cancer Screening: A Systematic Review.
Elemes S; Stachteas P; Haidich AB; Mamopoulos A; Smyrnakis E
In Vivo; 2023; 37(4):1455-1476. PubMed ID: 37369493
[TBL] [Abstract][Full Text] [Related]
54. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies.
Tekalegn Y; Sahiledengle B; Woldeyohannes D; Atlaw D; Degno S; Desta F; Bekele K; Aseffa T; Gezahegn H; Kene C
Womens Health (Lond); 2022; 18():17455065221075904. PubMed ID: 35114865
[TBL] [Abstract][Full Text] [Related]
55. Cervical Cancer Prevention, Its Challenges and Solutions in Iran and Worldwide: A Systematic Review.
Pirani N; Jafari M; Bagherzadeh R; Keikhosravi M; Pirani H
Iran J Public Health; 2023 Nov; 52(11):2313-2324. PubMed ID: 38106838
[TBL] [Abstract][Full Text] [Related]
56. Estimating a test's accuracy using tailored meta-analysis-How setting-specific data may aid study selection.
Willis BH; Hyde CJ
J Clin Epidemiol; 2014 May; 67(5):538-46. PubMed ID: 24447592
[TBL] [Abstract][Full Text] [Related]
57. Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study.
Hassanipour S; Zare R; Shahedi A; Delam H
Endocrine; 2023 Nov; 82(2):237-249. PubMed ID: 37269425
[TBL] [Abstract][Full Text] [Related]
58. New cervical cancer screening guidelines: do they signal the end of the annual pap test?
Waxman AG
J Low Genit Tract Dis; 2004 Apr; 8(2):87-90. PubMed ID: 15874843
[No Abstract] [Full Text] [Related]
59. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
60. Triage of high-risk HPV positive women in cervical cancer screening.
Ebisch RM; Siebers AG; Bosgraaf RP; Massuger LF; Bekkers RL; Melchers WJ
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1073-85. PubMed ID: 27598683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
